Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Hailey Wehner

Physician Assistant Goose Creek, SC Physician Assistant

NPI 1326756461 CMS profile 11407420

7 S Alliance Dr Ste 211B, Goose Creek, SC 29445

Open in the dashboard

General payments

$5,042

199 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hailey Wehner of Goose Creek, SC is reported in the CMS Open Payments database as having received $5,042 across 199 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,752 62
2024 General $1,764 71
2023 General $1,513 65
2022 General $13 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hailey Wehner
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Hailey Wehner were reported at $1,752. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Hailey Wehner Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $13 $155 $48–$522 $149
2023 $1,513 $167 $52–$557 $160
2024 $1,764 $178 $55–$600 $164
2025 $1,752 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AstraZeneca Pharmaceuticals LP $906 25 payments
  2. AbbVie, Inc. $823 40 payments
  3. Lilly USA, LLC $721 27 payments
  4. Novo Nordisk Inc $488 25 payments
  5. Otsuka America Pharmaceutical, Inc. $273 11 payments
  6. Pfizer Inc. $203 11 payments
  7. Exact Sciences Corporation $181 9 payments
  8. Genzyme Corporation $150 1 payment
  9. Philips Electronics North America Corporation $144 1 payment
  10. Cagent Vascular LLC $144 1 payment
  11. Other $1,010 48 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $5,042 199 payments
Products named General payments · program years 2022–2025
  1. FARXIGA $706 20 payments
  2. MOUNJARO $501 21 payments
  3. Ozempic $413 20 payments
  4. VRAYLAR $313 18 payments
  5. RYBELSUS $294 19 payments
  6. QULIPTA $279 11 payments
  7. UBRELVY $236 9 payments
  8. REXULTI $233 9 payments
  9. AIRSUPRA $227 4 payments
  10. NURTEC ODT $203 11 payments
  11. Other $2,715 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 70 drugs

Part D claims

2,071

Median for Physician Assistant: 241

Drug cost

$346,063

Median for Physician Assistant: $4,110

Branded share of claims

24.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 60 $89,401
Farxiga Dapagliflozin Propanediol Brand 79 $87,806
Jardiance Empagliflozin Brand 31 $45,691
Mounjaro Tirzepatide Brand 33 $42,469
Trulicity Dulaglutide Brand 27 $39,423
Eliquis Apixaban Brand 17 $19,624
Diovan Valsartan Brand 12 $3,489
Rosuvastatin Calcium Generic 137 $2,222
Albuterol Sulfate Hfa Albuterol Sulfate Brand 47 $1,599
Atorvastatin Calcium Generic 125 $914

The 10 drugs with the highest cost, of 70 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$55,365

Of which drugs: $1,047

Medicare patients

157

Average age 70

Services billed

1,191

106 women, 51 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 43%
Chronic kidney disease 35%
Arthritis 34%
Depression 20%
COPD 18%
Ischemic heart disease 17%
Osteoporosis 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from cell cultures 90661 Office 29 29 $1,047

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $364
$364 79 —
MOUNJARO
  • Lilly USA, LLC $171
$171 33 —
VRAYLAR
  • AbbVie, Inc. $155
$155 — —
JARDIANCE
  • Lilly USA, LLC $56
  • Boehringer Ingelheim Pharmaceuticals, Inc. $47
$103 31 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $83
$83 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

199 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record